白蛋白治疗时长对肝硬化合并急性肾损伤患者应答率及结局的影响
该研究基于德国两个中心前瞻性纳入的127例肝硬化合并急性肾损伤患者,评估白蛋白治疗24小时和48小时后的应答率,并比较三种应答定义的预后意义。结果显示30%–54%的患者对白蛋白治疗有应答,相当比例患者在48小时才应答,按定义3应答与更高的无血液透析和无移植生存率相关,缩短白蛋白疗程可能导致特利加压素过度治疗。
要点
- 肝硬化合并急性肾损伤患者中30%–54%对白蛋白治疗有应答,应答率在不同AKI分期之间均衡。
- 相当数量患者在48小时才应答,第二个24小时内按定义1、2、3的额外应答分别为28%、22%、18%。
- 按定义3(SCr下降至少一个AKI分期)应答与更高的无血液透析和无移植生存率相关。
核心结论
- 相当比例患者需要48小时才对白蛋白治疗产生应答,缩短白蛋白治疗时长可能导致特利加压素过度治疗。
研究设计与样本
- 研究分析了来自德国两个中心前瞻性招募的127例肝硬化合并急性肾损伤患者的数据。
- 在24小时和48小时后考察三种应答定义:(1)血清肌酐(SCr)下降>0.3 mg/dl;(2)SCr下降>25%;(3)SCr下降至少一个AKI分期。
- 随访持续至肝移植、死亡或血液透析。
主要发现
- 总体有30%–54%的患者对白蛋白治疗有应答,具体取决于所用定义,且应答率在不同AKI分期之间均衡。
- 相当数量在48小时应答的患者在最初24小时内未应答。
- 第二个24小时内按定义1、2、3对白蛋白的额外应答分别为28%、22%和18%。
- 按定义3应答与更高的无血液透析和无移植生存率相关。
临床怎么用
- 临床医生可利用这些发现更好地预测治疗结局、避免液体过负荷并改善患者预后,同时考虑早期使用特利加压素的潜在风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Guidelines recommended volume expansion with albumin for 48 hours for patients with cirrhosis and acute kidney injury (AKI) to correct hypovolemia and rule out prerenal AKI. A recent update in the ADQI-ICA consensus guidelines suggested shortening this duration to 24 hours, primarily based on expert opinion. This study aimed to evaluate the response rates to albumin treatment after 24 and 48 hours and to compare and assess the prognostic significance of three different definitions of response to albumin therapy. METHODS: Data from 127 prospectively recruited patients with cirrhosis and AKI from two German centers were analyzed. We examined three response definitions after 24 and 48 hours: (1) serum creatinine (SCr) decrease >0.3 mg/dl, (2) SCr decrease >25%, and (3) SCr decrease in at least one AKI stage. Follow-up was prolonged until liver transplantation, death or hemodialysis. RESULTS: Overall, 30-54% of the patients responded to albumin treatment depending on the definition, and response rates were balanced across AKI stages. Notably, a relevant number of patients who responded at 48 hours did not respond within the first 24 hours. Additional responses to albumin during the second 24 hours according to definitions 1, 2, and 3 were 28%, 22%, and 18%, respectively. Response according to definition 3 was associated with higher hemodialysis- and transplantation-free survival rates. CONCLUSION: A substantial proportion of patients require 48 hours to respond to albumin treatment. Shortening the duration of albumin therapy may lead to overtreatment with terlipressin. IMPACT AND IMPLICATIONS: This study provides valuable insights into the optimal duration of albumin treatment for patients with cirrhosis and acute kidney injury, challenging the recent recommendation to shorten the duration of albumin treatment. Furthermore, the optimal definition for response to albumin (reduction of at least one acute kidney injury stage) has been assessed. The results of this study are highly clinically relevant since shortening albumin therapy may lead to overtreatment with terlipressin, and evidence to support a specific definition of response to albumin was lacking. Clinicians can use these findings to predict treatment outcomes better, avoid fluid overload, and improve patient prognosis, while also considering the potential risks of early intervention with terlipressin.
引用
- Schleicher EM, Karbannek H, Weinmann-Menke J, et al. Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury. J Hepatol. 2025. PMID: 40118117. doi:10.1016/j.jhep.2025.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。